Table 3.
Treatment failure
| Year |
||||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| Any reason | ||||||
| Valproate | ||||||
| Number at risk | 165 | 114 | 61 | 40 | 14 | 4 |
| Percentage still on drug (95% CI) | 74 (68 to 79) | 67 (61 to 73) | 61 (54 to 68) | 60 (52 to 67) | 58 (50 to 66) | 58 (50 to 66) |
| Lamotrigine | ||||||
| Number at risk | 152 | 106 | 60 | 29 | 10 | 3 |
| Difference in percentage without failure compared with valproate (95% CI) | −5 (−13 to 3) | −6 (−15 to 3) | −6 (−16 to 4) | −10 (−21 to 1) | −8 (−20 to 3) | −8 (20 to 3) |
| Topiramate | ||||||
| Number at risk | 129 | 91 | 55 | 35 | 13 | 1 |
| Difference in percentage without failure compared with valproate (95% CI) | −14 (−23 to −6) | −14 (−23 to −5) | −11 (−21 to −2) | −11 (−21 to −1) | −13 (−24 to −2) | −16 (−29 to −4) |
| For adverse events | ||||||
| Valproate | ||||||
| Percentage without failure (95% CI) | 84 (79 to 89) | 82 (77 to 87) | 79 (73 to 85) | 79 (73 to 85) | 79 (73 to 85) | 79 (73 to 85) |
| Lamotrigine | ||||||
| Difference in percentage without failure compared with valproate (95% CI) | 3 (−3 to 10) | 5 (−2 to 11) | 7 (−1 to 14) | 7 (−1 to 14) | 7 (−1 to 14) | 7 (−1 to 14) |
| Topiramate | ||||||
| Difference in percentage without failure compared with valproate (95% CI) | −9 (−16 to −1) | −10 (−18 to −2) | −8 (−16 to 1) | −8 (−16 to 1) | −8 (−16 to 1) | −14 (−30 to 1) |
| For inadequate seizure control | ||||||
| Valproate | ||||||
| Percentage without failure (95% CI) | 90 (87 to 94) | 87 (82 to 91) | 84 (79 to 89) | 84 (79 to 89) | 84 (79 to 89) | 84 (79 to 89) |
| Lamotrigine | ||||||
| Difference in percentage without failure compared with valproate (95% CI) | −7 (−13 to −1) | −10 (−17 to −3) | −13 (−21 to −4) | −15 (−24 to −6) | −15 (−24 to −6) | −15 (−24 to −6) |
| Topiramate | ||||||
| Difference in percentage without failure compared with valproate (95% CI) | −6 (−12 to 0) | −5 (−12 to 2) | −5 (−12 to 3) | −5 (−12 to 3) | −5 (−12 to 3) | −9 (−19 to 2) |